| Conclusions
(cont.) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| • | KIT
exon 9 mutant isoforms are drug |
||||||||||||
| sensitive
in vitro, but tumors with this |
|||||||||||||
| mutation
appear less responsive in |
|||||||||||||
| patients |
|||||||||||||
| – | Exon
9 mutations are found only in |
||||||||||||
| small
bowel and colonic GISTs |
|||||||||||||
| – | Preliminary
data suggest differences in |
||||||||||||
| downstream
signaling intermediates |
|||||||||||||
| (J.
Fletcher & M. Heinrich) |
|||||||||||||